All In Biotech

Drug Trial Radar · NCT00090259

Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)

A Multi-center, Double-Blind, Randomized, Parallel Group Study to Evaluate the Effects of Two Different Doses of Losartan on Morbidity and Mortality in Patients With Symptomatic Heart Failure Intolerant of ACE Inhibitor Treatment

Last checked: Nov 19, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,834 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,834

Actual

Start

Dec 19, 2001

Primary completion

Mar 31, 2009

Study completion May 13, 2009

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Aug 27, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter study to evaluate potential decrease in hospitalization events and time between events and increasing longevity in patients with symptomatic congestive heart failure and intolerant of first-line medication for heart failure. This study will evaluate if higher doses of the investigational drug given daily will be superior to the lower dose of the same investigational drug given daily.

Conditions

  • Heart Failure

Interventions

  • Losartan 50 mgDrug

    50-mg losartan oral tablet

  • Losartan 150 mgDrug

    100-mg losartan oral tablet + 50-mg losartan oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart FailureTime frame: Entire follow-up (median = 4.7 years)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.